Home/Lyra Therapeutics/Maria Palasis, Ph.D.
MP

Maria Palasis, Ph.D.

President, Chief Executive Officer, and Director

Lyra Therapeutics

Lyra Therapeutics Pipeline

DrugIndicationPhase
LYR-210Chronic Rhinosinusitis (CRS)Phase 3
LYR-220Chronic Rhinosinusitis (CRS)Not Specified (Pipeline)